Clinical Diagnostic Laboratories Face July 31 Deadline: What CMS's PAMA Data Reporting Requirement Means for Labs, Physician Offices, and Medicare's Lab Payment Rates

The Centers for Medicare & Medicaid Services (CMS) is reminding independent laboratories, physician office laboratories, and hospital outreach laboratories that meet the federal definition of an "applicable laboratory" that they face a hard deadline: private payor rate and volume data must be reported to CMS by July 31, 2026, or the laboratory may be subject to civil monetary penalties. The reminder, published in the July 23, 2026 edition of CMS's MLN Connects newsletter, is the latest checkpoint in a reporting system that has quietly determined how Medicare pays for clinical laboratory tests since 2018.

The requirement traces back to the Protecting Access to Medicare Act of 2014 (PAMA), which replaced the government's older, historically-set fee schedule for clinical laboratory tests with a market-based system tied to what private insurers actually pay. To make that system work, CMS needs laboratories to periodically report the rates private payors paid them and the volume of tests billed at each rate — data CMS then uses to recalculate the Medicare Clinical Laboratory Fee Schedule (CLFS) itself. Below, HealthBridge US explains who has to report, what has to be reported, how the reporting system works, what happens if a laboratory doesn't comply, and what this reporting cycle means for the future of Medicare's laboratory payment rates.

Quick-Read Summary

Before the details, here is the essential rundown of what's required. Independent laboratories, physician office laboratories, and hospital outreach laboratories that meet the definition of an "applicable laboratory" under the Clinical Laboratory Fee Schedule must report private payor rate and volume data to CMS by July 31, 2026. The data being reported covers a defined data collection period — January 1 through June 30, 2025 — and must include the applicable HCPCS billing codes for each test, every private payor rate the laboratory received final payment at during that window, and the volume of tests billed at each of those rates. Laboratories report through CMS's CLFS Data Collection System, which requires separate identity-verification registration for two distinct user roles: a submitter, who enters the data, and a certifier, who attests to its accuracy before final submission. CMS has published applicable HCPCS code lists, a standardized data reporting template, user manuals, and instructional videos to support the process, and has also updated its PAMA reporting FAQ document, adding new guidance on which tests are covered, how to report aggregate versus itemized payor rates, and whether laboratories may upload multiple files under a single Taxpayer Identification Number. Laboratories that fail to report, or that misrepresent or omit required information, are subject to civil monetary penalties of up to $10,000 per day per violation, adjusted annually for inflation. The data collected in this cycle will feed into a CMS review process later in 2026 that determines updated Medicare payment rates for laboratory tests effective January 1, 2027.

Why This Requirement Exists

To understand why CMS is chasing this data every few years, it helps to understand what changed in 2014. Before PAMA, Medicare set clinical laboratory test payment rates using a historically-based fee schedule that had been updated incrementally for decades, largely disconnected from what laboratories were actually being paid by private insurers in the commercial market. Congress concluded that Medicare was, in many cases, paying more for common lab tests than private payors were, and passed PAMA specifically to move Medicare's laboratory payment system onto a market-based footing.

Section 216 of PAMA added Section 1834A to the Social Security Act, directing CMS to build a new Clinical Laboratory Fee Schedule payment methodology based on the weighted median of private payor rates that laboratories actually receive for each test, collected through a mandatory data reporting system. Rather than CMS or Congress setting laboratory payment rates through the traditional rulemaking or legislative process, the market itself — as reflected in the rates commercial insurers pay laboratories — now drives what Medicare pays for the same tests, provided CMS can collect accurate, representative data on those private-sector rates.

That data-dependency is precisely why the reporting requirement carries real legal weight. If a meaningful share of applicable laboratories failed to report, or reported inaccurate data, the resulting Medicare payment rates would no longer reflect an accurate picture of the private market CMS is trying to track. The reporting requirement, and the civil monetary penalties that back it up, exist to keep the underlying data pool reliable enough to support this market-based ratesetting model.

Government auditors had flagged the gap between Medicare and private-market laboratory pricing well before PAMA passed. Reviews by the Government Accountability Office and the HHS Office of Inspector General in the years leading up to 2014 repeatedly found that Medicare's historically-set CLFS rates for many common, high-volume tests — including routine chemistry panels and basic blood tests — exceeded what state Medicaid programs, federal employee health plans, and private commercial insurers were paying for the same tests, in some cases by a substantial margin. Those findings gave Congress the evidentiary basis to conclude that Medicare could achieve savings without compromising beneficiary access to laboratory testing simply by pricing its own fee schedule closer to what the broader market was already paying — provided CMS had a reliable, ongoing mechanism for finding out what the market was actually paying. The applicable laboratory reporting requirement is that mechanism.

How CMS Calculates the Resulting Medicare Rate

The mechanics of how reported data becomes a Medicare payment rate are worth understanding, both because they explain why CMS insists on rate-level rather than aggregated reporting, and because they clarify what "weighted median" actually means in practice. For each HCPCS test code, CMS collects every private payor rate reported by every applicable laboratory nationally, along with the volume of tests each laboratory billed at each of those rates. CMS then arrays all of those individual rate-and-volume data points from lowest to highest reported rate, and identifies the rate at which cumulative reported volume crosses the 50th percentile of total national volume for that test — the volume-weighted median, rather than a simple average of the reported rates themselves.

To illustrate with a simplified, hypothetical example: if three applicable laboratories nationally reported a particular test at three different private payor rates — one at $20 per test across a high volume of claims, one at $25 across a moderate volume, and one at $35 across a small volume — the weighted median calculation would land at whichever of those rates corresponds to the midpoint of total reported volume, not simply the mathematical average of $20, $25, and $35. A laboratory with a very high reported volume at a lower rate can therefore pull the resulting national Medicare rate down more than a laboratory reporting a higher rate at low volume would pull it up, which is precisely why volume data, not just rate data, is a mandatory reporting field, and why CMS's updated FAQ guidance insists on rate-by-rate reporting rather than an aggregated total: an aggregated single figure would strip out the volume-weighting information the methodology depends on.

This methodology also explains why CMS treats "final payment" as the relevant standard for which private payor rates must be reported. A rate is only reportable once a private payor has made final payment on a claim during the data collection period — meaning rates that are still pending adjudication, under appeal, or otherwise not yet finalized as of June 30, 2025, generally fall outside the scope of what an applicable laboratory reports for this cycle, since CMS's methodology is built around rates that reflect a completed, real transaction between the laboratory and the private payor rather than a billed or proposed amount.

What This Means for Referring Physicians and Patients

Although the reporting requirement itself is a laboratory-side compliance obligation, its downstream effects reach referring physicians and Medicare beneficiaries as well, even though neither group has any direct reporting role. Medicare beneficiaries generally do not pay coinsurance or a deductible for clinical diagnostic laboratory tests covered under Part B, since Congress has long exempted most CLFS-covered tests from standard Part B cost-sharing; as a result, changes to CLFS payment rates driven by this reporting cycle affect what Medicare and the laboratory are paid for a given test, rather than what a beneficiary pays out of pocket in most cases. Where the reporting cycle's resulting rate changes matter most directly for beneficiaries is in the more indirect question of laboratory access and network stability: significant downward rate adjustments, particularly for lower-margin, high-volume routine tests, have been cited by some laboratory operators and rural health advocates in past reporting cycles as a factor affecting the financial viability of maintaining testing capacity in lower-volume or rural markets, where a laboratory's Medicare beneficiary population represents a larger share of its overall patient base than in urban markets with more diverse payor mixes.

For referring physicians, particularly those in primary care, hospital medicine, and other specialties that order high volumes of routine laboratory testing, the CLFS rate-setting process happening behind this reporting cycle has no immediate day-to-day effect on ordering practices or documentation requirements. The more relevant long-term consideration is systemic: physician practices that operate their own in-office laboratories — and that therefore may themselves meet the applicable laboratory definition described earlier in this article — need to evaluate their own reporting obligations directly, separate from any effect the resulting rates might have on outside reference laboratories they refer testing to.

Who Has to Report: The "Applicable Laboratory" Definition

Not every laboratory that bills Medicare is required to report under this system. CMS's reporting obligation is limited to entities that meet the specific regulatory definition of an "applicable laboratory," a term with several distinct components that a lab, physician office, or hospital outreach laboratory must satisfy simultaneously.

First, the entity performing the tests must be certified under the Clinical Laboratory Improvement Amendments (CLIA), the federal law governing laboratory testing quality standards. Second, the tests performed by that CLIA-certified laboratory must be billed to Medicare Part B under its own individual National Provider Identifier (NPI), rather than being billed through another entity's provider number. Third, the laboratory must meet what CMS calls the "majority of Medicare revenues" threshold — meaning the majority of its total Medicare revenue, across both Part A and Part B, must come from payments made under the Clinical Laboratory Fee Schedule and the Medicare Physician Fee Schedule combined, rather than from other Medicare payment systems. Notably, Medicare Advantage plan payments are excluded from the calculation of total Medicare revenues used in that threshold test.

Fourth, and finally, the laboratory must meet the "low expenditure threshold" — it must have received at least $12,500 in Medicare revenue specifically from the Clinical Laboratory Fee Schedule during the applicable data collection period. This threshold exists to exclude very low-volume Medicare billers from the reporting burden, on the theory that their data would have minimal effect on the weighted median rates CMS calculates nationally, while still capturing the large majority of Medicare's actual laboratory spending.

A laboratory, physician office laboratory, or hospital outreach laboratory that meets all four conditions is an "applicable laboratory" and is legally required to report under this cycle. Because the definition turns on an entity's actual billing pattern and revenue mix during the data collection period rather than any single, easily checked characteristic like size or ownership type, CMS has repeatedly emphasized — including through its updated FAQ document — that laboratories need to affirmatively evaluate their own status against these criteria rather than assume the requirement does or doesn't apply to them based on general impressions of their business.

Why the Data Matters: CLFS Spending and Rate History

Clinical laboratory testing is not a small line item in Medicare's budget. According to a Department of Health and Human Services Office of Inspector General analysis, Medicare Part B spent roughly $8.0 billion on clinical laboratory tests paid under the CLFS in 2023 alone — a figure that had actually declined about 5.4% from 2022, but that still represents billions of dollars in payments flowing to thousands of laboratories nationwide each year, all priced off the CLFS rates that this reporting cycle will help determine.

The stakes around reporting accuracy are heightened by the CLFS's rate-reduction history. When PAMA's market-based rates first took effect, Congress capped how quickly Medicare's laboratory payment rates could fall in any single year, recognizing that an unconstrained shift to weighted-median private-payor rates could cause large, disruptive one-year swings for laboratories reliant on Medicare billing. CLFS rates were capped at reductions of no more than 10% per year in each of 2018, 2019, and 2020, the first three years of the market-based system. Congress and CMS subsequently extended and adjusted that phase-in schedule multiple times in response to industry concerns and, more recently, pandemic-era disruptions to normal laboratory operations and billing patterns. Under current law, including the Consolidated Appropriations Act, 2026 provisions referenced earlier in this article, CLFS rates face no scheduled reduction in 2026, with a 15%-per-year reduction cap set to apply again beginning in 2027 and continuing through 2029.

Because the rate-reduction caps are anchored to the reporting cycle's weighted-median calculations, the accuracy of what applicable laboratories report by July 31, 2026 has a direct, multi-year bearing on how the resulting CLFS rates move relative to current levels, and on how much of any downward adjustment laboratories actually feel starting January 1, 2027.

Advanced Diagnostic Laboratory Tests: A Separate, Faster-Moving Track

Not every laboratory test moves through the same reporting and payment cycle. PAMA created a distinct payment and reporting category for Advanced Diagnostic Laboratory Tests (ADLTs) — tests that are only available from a single laboratory (a "single-source" test), typically involving proprietary molecular or genomic analysis, and that meet additional statutory criteria distinguishing them from conventional Clinical Diagnostic Laboratory Tests (CDLTs), the broader category most lab tests fall into and the category most directly affected by the July 31, 2026 reporting deadline discussed in this article.

ADLTs are treated differently in two important respects. When an ADLT is first introduced, CMS initially pays for it at the laboratory's own list price for a set introductory period, rather than waiting for private payor market data to accumulate. After that introductory period, however, the laboratory that furnishes the ADLT is required to report its applicable private payor rate and volume information to CMS on an annual basis — a much more frequent reporting cadence than the multi-year cycle that governs most CDLTs, including the tests covered by this current reporting deadline. As of CMS's most recent published counts, only a small number of tests nationally — 19, according to CMS's current ADLT list — carry this designation, meaning the overwhelming majority of applicable laboratories reporting by July 31, 2026 are reporting CDLT data under the standard multi-year cycle described throughout this article, not ADLT data under the separate annual track.

What Data Has to Be Reported

For applicable laboratories, the reporting obligation covers a defined data collection period: January 1, 2025, through June 30, 2025. For every laboratory test the applicable laboratory performed during that six-month window, it must report three linked pieces of information to CMS.

The first is the specific Healthcare Common Procedure Coding System (HCPCS) code associated with the test — the billing code that identifies precisely which laboratory test was performed. The second is every private payor rate for which the laboratory received final payment during the data collection period for that test, meaning the actual negotiated or paid rate from each commercial or other private insurer, not a list price or a single averaged figure. The third is the volume of tests performed that correspond to each of those reported private payor rates — in other words, not just what rates were paid, but how many tests were billed at each specific rate, since CMS uses volume-weighted calculations to determine the eventual Medicare payment rate.

CMS has published a defined list of applicable HCPCS codes subject to this reporting cycle, along with a standardized Data Reporting Template, to help laboratories organize this information into the format CMS's system expects before submission.

How Laboratories Actually Submit the Data

Reporting happens through CMS's CLFS Data Collection System, a dedicated online portal built specifically for this purpose. Before a laboratory can submit anything, its designated personnel must complete an Identity Management (IDM) registration process, which CMS has documented in a dedicated registration guide to walk organizations through the account-setup steps.

The system is built around two distinct user roles, and CMS requires both to be involved before data is considered formally submitted. The submitter role is responsible for entering the laboratory's HCPCS codes, private payor rates, and volume data into the system, following the Data Reporting Template format; CMS has published both a written user manual and a demonstration video specifically for this role. The certifier role is separate and carries legal significance: the certifier reviews and formally attests to the accuracy of the data the submitter has entered before it is finalized, and CMS has likewise published a dedicated user manual and demonstration video for that role. In practice, this two-role structure means most applicable laboratories will need at least two designated staff members, or a staff member and an authorized organizational official, involved in the reporting process — one to compile and enter the data, and a separate individual empowered to certify its accuracy on the laboratory's behalf.

CMS has also published a separate training video walking through use of the Data Reporting Template itself, aimed at helping laboratory billing and compliance staff correctly map their internal payor-rate and volume data into the fields CMS's system requires.

The Updated FAQ Document: What Changed

Alongside the reporting window, CMS maintains a detailed Frequently Asked Questions document addressing common technical and interpretive questions about the reporting requirement, and it updated Section 4 of that document ahead of this reporting deadline. Three changes are worth flagging specifically.

CMS revised its answer to the question of where laboratories can find the list of tests actually subject to the data collection and reporting requirements, pointing applicable laboratories toward the current applicable HCPCS code list rather than older or general laboratory billing code references. CMS also added new guidance addressing a recurring point of confusion: whether laboratories should report each individual private payor rate separately, or instead report a single total amount of payment collected across payors for a given test. The new FAQ answer clarifies CMS's expectation that laboratories report at the level of individual private payor rates and their associated volumes, rather than an aggregated total, since the weighted-median methodology CMS uses to set Medicare rates depends on seeing the actual distribution of individual negotiated rates rather than a blended figure. Finally, CMS added new guidance on a practical data-management question: whether a laboratory can upload multiple files under a single Taxpayer Identification Number (TIN) when submitting its data, which matters for larger laboratory organizations or hospital systems managing multiple service lines or reporting periods' worth of data under one umbrella TIN.

The Civil Monetary Penalty Exposure

CMS's authority to enforce this reporting requirement is not merely administrative. Under the statute, CMS may impose civil monetary penalties of up to $10,000 per day for each failure to report and for each misrepresentation or omission in data that is reported, with that maximum dollar figure subject to mandatory annual adjustment for inflation under the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015. Because the penalty structure is denominated per day and applies separately to reporting failures and to inaccuracies or omissions within a submitted report, the potential financial exposure for an applicable laboratory that simply misses the deadline, rather than submitting inaccurate data, can escalate quickly the longer noncompliance continues.

This penalty structure is also why CMS's messaging around this deadline — including the MLN Connects reminder that prompted this article — is framed with real urgency rather than as a routine administrative notice. An applicable laboratory that has not yet determined whether it meets the definition, has not gathered its private payor rate and volume data for the January through June 2025 window, or has not completed the IDM registration and submitter/certifier account setup, faces a compressed timeline to avoid triggering per-day penalty exposure once the July 31 deadline passes.

What Happens to the Data After Reporting

The private payor rate and volume data collected through this reporting cycle does not sit idle once submitted. CMS uses the reported data to recalculate the Medicare Clinical Laboratory Fee Schedule payment rate for each affected test, based on the weighted median of the private payor rates reported nationally for that test, weighted by the reported volumes.

That recalculation process unfolds over the months following the reporting deadline. CMS analyzes the newly collected data over the summer following the close of the reporting window, and typically convenes a public meeting — often involving CMS's Federal Advisory Committee Act (FACA) advisory panel on clinical laboratory tests — in the fall to review proposed payment determinations before they are finalized. Updated CLFS payment rates based on this reporting cycle's data are expected to take effect January 1, 2027, meaning the accuracy and completeness of what laboratories report by the July 31, 2026 deadline will directly shape what Medicare pays for laboratory tests nationwide for years afterward, since CLFS reporting cycles occur only periodically rather than annually.

It's worth noting for context that separate from this reporting cycle, recent federal legislation has already shaped the near-term trajectory of CLFS payment rates themselves: under the Consolidated Appropriations Act, 2026, there are no scheduled CLFS payment rate reductions during 2026, with the phase-in of previously scheduled rate reductions pushed out to resume in 2027 through 2029. That legislative delay affects the pace at which any downward rate adjustments take effect, but it does not affect the underlying reporting obligation covered in this article, which continues on its own statutory and regulatory timeline regardless of the phase-in schedule for rate reductions.

A Brief History of PAMA Reporting Cycles

The reporting cycle culminating in the July 31, 2026 deadline is not the first, and understanding a bit of that history helps explain why the cadence can be confusing for laboratories encountering the requirement for the first time. CMS's original PAMA reporting cycle collected private payor data from the first half of 2016 and used it to set new, market-based CLFS rates beginning January 1, 2018 — the initial transition away from the old historical fee schedule.

Congress subsequently revised the reporting cadence through the Laboratory Access for Beneficiaries Act (the "LAB Act"), enacted in late 2019, which shifted most applicable laboratories from an originally annual reporting expectation to a triennial — once every three years — cycle for many test categories, easing the ongoing administrative burden on laboratories while still keeping CLFS rates tied to updated market data on a recurring basis. Under that revised schedule, the next data collection period was set to run from January through June 2019, with laboratories reporting that data to CMS in early 2020 and revised rates taking effect the following year.

That second cycle, however, did not unfold on schedule. The onset of the COVID-19 pandemic in 2020, and the resulting disruption to normal laboratory billing and operations as labs redirected substantial capacity toward pandemic testing, prompted Congress to intervene repeatedly through successive pieces of relief and appropriations legislation, delaying both the reporting deadline for that 2019 data and the effective date of the resulting rate changes multiple times over roughly two years. Reporting on that delayed cycle ultimately occurred in early 2022, still based on the original January through June 2019 data collection period, with the resulting updated rates taking effect January 1, 2023.

That delay history set up the confusion surrounding this current cycle. Under the LAB Act's triennial schedule, the next reporting cycle after the 2022 filing would ordinarily have used a 2022 data collection period; instead, industry legal and compliance publications reported that, absent further congressional action, laboratories faced the prospect of having to report using the same aging January through June 2019 data collection period yet again, with a reporting window originally anticipated to open in February 2026 — years further removed from current market pricing than the system was designed to tolerate. Congress ultimately intervened again ahead of that scheduled window, updating the applicable data collection period to January through June 2025 rather than the older 2019 data, which produced the reporting window this article addresses: submissions opening May 1, 2026, and closing July 31, 2026. For applicable laboratories, the practical takeaway is that both the reporting deadlines themselves and the vintage of data being reported have shifted more than once in response to legislative action, making it important for laboratory compliance staff to confirm current deadlines and data collection periods directly against CMS's published guidance for each cycle rather than assume a fixed, unchanging schedule based on a prior cycle's experience.

The table below summarizes how the three PAMA reporting cycles to date compare, illustrating both the triennial design Congress intended and the repeated delays that have, in practice, stretched the interval between cycles well beyond three years on more than one occasion.
Timeline: What Happens When

January 1, 2025 – June 30, 2025 — The data collection period. Applicable laboratories must track every private payor rate they receive final payment at, and the corresponding test volumes, for services furnished during this window.

Ahead of the reporting window — CMS publishes and updates supporting resources, including the applicable HCPCS code list, the Data Reporting Template, IDM registration instructions, submitter and certifier user manuals and demonstration videos, and the PAMA reporting FAQ document, most recently updated July 14, 2026.

July 23, 2026 — CMS publishes a reminder in its MLN Connects newsletter urging applicable laboratories to complete their reporting ahead of the deadline, the notice this article is based on.

By July 31, 2026 (11:59 p.m. Eastern) — Applicable laboratories must complete submission and certification of their private payor rate and volume data through the CLFS Data Collection System. Laboratories that fail to report, or that submit inaccurate or incomplete data, become subject to civil monetary penalty exposure of up to $10,000 per day, adjusted for inflation, per violation.

Summer 2026 — CMS analyzes the newly collected reporting data nationally.

Fall 2026 — CMS convenes a public meeting, typically involving its clinical laboratory tests advisory panel, to review proposed Medicare payment rate determinations based on the new data, before finalizing them.

January 1, 2027 — Updated Clinical Laboratory Fee Schedule payment rates, based on this reporting cycle's data, take effect. This is also the date on which the currently paused CLFS rate-reduction phase-in is scheduled to resume, with reductions capped at 15% per year through 2029.

Industry Context: A Recurring Compliance Cycle

The lab industry has closely tracked PAMA reporting cycles since the requirement first took effect, and industry trade associations — representing independent laboratories, hospital-based laboratories, and physician office laboratories alike — have periodically raised concerns with Congress and CMS about aspects of the reporting and rate-setting system, even as they have generally not disputed the underlying goal of tying Medicare rates to private market data. Some of the more persistent industry concerns, raised across multiple past reporting cycles, have centered on whether the reporting requirement's structure adequately captures rates from the full range of laboratories that serve Medicare beneficiaries — since hospital outreach laboratories and physician office laboratories, which the reporting requirement explicitly covers, have historically reported at lower rates of participation than large independent reference laboratories, potentially skewing the resulting weighted-median calculations toward the segment of the industry that reports most consistently.

That concern is part of why CMS's reminders ahead of each reporting deadline, including the one prompting this article, explicitly name independent laboratories, physician office laboratories, and hospital outreach laboratories together, rather than addressing only the large national reference laboratory chains most commonly associated with clinical lab testing in the public's mind. A hospital-based outreach laboratory or a physician office running in-house testing can just as easily meet the "applicable laboratory" definition as a large independent lab, and CMS's outreach in this cycle reflects an effort to reach that broader, more dispersed population of reporting-eligible entities.

Separately, industry groups have also engaged with Congress on more structural reforms to the PAMA reporting and rate-setting system beyond any single reporting cycle, including proposals addressing reporting frequency, the definition of applicable laboratory, and the phase-in schedule for rate reductions. Those broader legislative reform discussions are ongoing and distinct from the specific July 31, 2026 reporting deadline covered in this article, which proceeds under current law regardless of the status of any pending reform proposals.

What Laboratories and Physician Offices Should Do Now

For any independent laboratory, physician office laboratory, or hospital outreach laboratory that has not yet confirmed its reporting status, the first step is a straightforward internal assessment against the four-part applicable laboratory definition: CLIA certification status, individual NPI billing, the majority-of-Medicare-revenues threshold, and the $12,500 low expenditure threshold for the January through June 2025 data collection period. Laboratories that determine they do meet the definition, and have not yet begun the reporting process, should treat IDM registration as an immediate first step, since account setup for both the submitter and certifier roles needs to be completed before any data can actually be entered into the CLFS Data Collection System.

Billing and compliance staff should next assemble the required data set — HCPCS codes, individual private payor rates, and corresponding volumes for the January through June 2025 period — using CMS's Data Reporting Template as the organizing format, referencing the applicable HCPCS code list to confirm which specific tests fall within scope. Given the updated FAQ guidance clarifying that individual payor rates, not aggregated totals, are what CMS expects, laboratories that have been tracking payor data at a summary level should confirm their internal data can be broken out to the individual-rate level CMS's system requires before the submission window closes.

Organizations managing multiple laboratory locations, service lines, or reporting periods under a single Taxpayer Identification Number should also review CMS's new FAQ guidance on multiple-file uploads under one TIN, since that guidance directly addresses how larger or multi-site organizations should structure their submissions. Finally, given the per-day, per-violation structure of the civil monetary penalty exposure, laboratory compliance and legal teams should build in enough internal review time before July 31 to catch data errors or omissions prior to certification, rather than treating the certifier's attestation as a formality — since misrepresentations or omissions in submitted data carry the same penalty exposure as failing to report at all.

Common Compliance Pitfalls in Past Reporting Cycles

Laboratory billing and compliance consultants who have advised applicable laboratories through prior PAMA reporting cycles have flagged a recurring set of avoidable errors, several of which are directly addressed in CMS's updated FAQ guidance for this cycle. The most basic is simply failing to determine applicable laboratory status in the first place — a laboratory that assumes the requirement applies only to large national reference labs, or only to freestanding independent labs rather than hospital outreach or physician office labs, can miss the requirement entirely until a penalty notice arrives.

A second common error involves reporting aggregated or averaged payment data instead of rate-by-rate figures, the exact issue CMS's newly added FAQ guidance on this point is designed to head off; laboratories that maintain payor-rate data at a summary level for internal accounting purposes need to confirm their systems can break that data out to the individual-rate, individual-volume level the CLFS Data Collection System requires before the reporting window closes, rather than discovering the gap while attempting final submission. A third recurring issue involves the submitter-certifier workflow itself: because certification is a distinct, legally significant step from data entry, laboratories that treat certification as a rubber-stamp formality — rather than building in a genuine internal review between submission and certification — run a higher risk of certifying data that contains errors, which carries the same penalty exposure under the statute as never having reported at all.

Finally, organizations managing multiple laboratory locations or service lines under a single Taxpayer Identification Number have, in past cycles, sometimes struggled with how to structure multi-site submissions correctly, which is precisely the gap CMS's new FAQ guidance on multiple-file uploads under one TIN is intended to close for this reporting cycle. Laboratory organizations in that position should review that specific FAQ guidance closely rather than defaulting to whatever approach they may have used, informally or otherwise, in a previous reporting cycle.

The Bigger Picture

This reporting cycle is a reminder that Medicare's clinical laboratory payment rates are not set through the kind of annual rulemaking process that governs many other parts of the Medicare fee-for-service system. Instead, since PAMA's enactment, they are built directly from data that thousands of individual laboratories, physician offices, and hospital outreach labs across the country are legally required to self-report on a periodic basis. When that self-reported data is complete and accurate, the resulting Medicare rates are designed to track the private commercial market closely. When a meaningful share of applicable laboratories fail to report, or report inaccurately, the resulting national weighted-median rates rest on a narrower and potentially less representative data pool — which is precisely the risk CMS's civil monetary penalty authority, and its periodic public reminders like the one that prompted this reporting cycle's July 31, 2026 deadline, are designed to guard against.

For laboratories, the requirement is best understood as a recurring compliance obligation tied directly to the laboratory's own Medicare billing activity, rather than a one-time registration or a requirement limited to large national reference laboratories. Independent labs, physician office labs, and hospital outreach labs alike can find themselves squarely within the applicable laboratory definition depending on their specific billing mix and revenue thresholds during the relevant data collection period — which is exactly why CMS continues to emphasize, cycle after cycle, that laboratories need to check their own status rather than assume the obligation applies only to someone else.

The repeated legislative delays that shaped this cycle's path to a July 31, 2026 deadline also illustrate a broader tension running through the PAMA reporting system: a rate-setting methodology built on the premise of tracking current private-market pricing is only as accurate as its most recent data collection period, and a system that was designed to refresh that data every three years has, in practice, gone considerably longer between some cycles due to intervening legislative and public-health disruptions. That history is part of why this cycle's shift back to a current, 2025 data collection period — rather than continuing to rely on 2019 figures — was treated as meaningful news within the laboratory industry, even though the basic reporting mechanics applicable laboratories must follow remain largely unchanged from prior cycles.

Frequently Asked Questions

What is the PAMA/CLFS reporting requirement? It is a federal requirement, established under the Protecting Access to Medicare Act of 2014, that laboratories meeting the definition of an "applicable laboratory" periodically report their private payor rates and test volumes to CMS, which CMS then uses to set market-based Medicare payment rates under the Clinical Laboratory Fee Schedule.

Who has to report by July 31, 2026? Any independent laboratory, physician office laboratory, or hospital outreach laboratory that qualifies as an "applicable laboratory" — meaning it is CLIA-certified, bills Medicare Part B under its own NPI, derives the majority of its Medicare revenue from the CLFS and Physician Fee Schedule combined, and received at least $12,500 in Medicare CLFS revenue during the data collection period.

What time period does the reported data cover? The data collection period is January 1, 2025, through June 30, 2025. Reports covering that period are due to CMS by July 31, 2026.

What specific data must be reported? For each applicable HCPCS test code, the laboratory must report every private payor rate it received final payment at during the data collection period, along with the volume of tests billed at each of those rates.

How do laboratories submit their data? Through CMS's CLFS Data Collection System, after completing Identity Management (IDM) registration. The system requires a submitter, who enters the data, and a separate certifier, who attests to its accuracy before final submission.

What happens if a laboratory doesn't report, or reports inaccurate data? CMS may impose civil monetary penalties of up to $10,000 per day, adjusted annually for inflation, for each failure to report and for each misrepresentation or omission in reported data.

What does CMS do with the reported data? CMS uses the weighted median of reported private payor rates, weighted by reported volumes, to recalculate Medicare Clinical Laboratory Fee Schedule payment rates. Updated rates from this reporting cycle are expected to take effect January 1, 2027.

Are CLFS payment rates being cut in 2026? No. Under the Consolidated Appropriations Act, 2026, scheduled CLFS payment rate reductions did not take effect in 2026; the phase-in of those reductions has been pushed to resume in 2027 through 2029. That delay is separate from, and does not affect, the reporting obligation itself.

Where can laboratories find CMS's reporting resources? CMS's CLFS & PAMA Reporting and Resources webpage hosts the applicable HCPCS code list, the Data Reporting Template, IDM registration guidance, submitter and certifier user manuals and demonstration videos, and the updated PAMA reporting FAQ document.

What is the difference between a CDLT and an ADLT for reporting purposes? Clinical Diagnostic Laboratory Tests (CDLTs) are the broad category of lab tests covered by the multi-year reporting cycle described in this article. Advanced Diagnostic Laboratory Tests (ADLTs) are single-source, typically molecular or genomic tests that are initially paid at list price and then reported annually rather than on the standard multi-year CDLT cycle. Only a small number of tests nationally — 19, as of CMS's current list — carry ADLT status.

How much does Medicare spend on clinical laboratory tests each year? Medicare Part B spent approximately $8.0 billion on CLFS-covered clinical laboratory tests in 2023, according to a Department of Health and Human Services Office of Inspector General analysis — a decrease of about 5.4% from 2022 spending levels.

Does a physician office laboratory really need to worry about this requirement? Yes, if it meets the applicable laboratory definition. CMS's reminder explicitly names physician office laboratories, alongside independent and hospital outreach laboratories, as entities that must evaluate their reporting status; the requirement is not limited to large national reference laboratory chains.

What is the submitter and certifier role, and why does CMS require both? The submitter enters a laboratory's HCPCS codes, private payor rates, and test volumes into the CLFS Data Collection System. The certifier is a separate individual who formally attests to the accuracy of that submitted data before it is finalized. Requiring both roles builds an internal accuracy check into the submission process itself, given that misrepresentations or omissions carry the same civil monetary penalty exposure as failing to report entirely.

Why is this reporting cycle using data from 2025 instead of a more recent period, or the originally scheduled 2019 data? The LAB Act set applicable laboratories on a triennial reporting schedule, but successive rounds of federal legislation — beginning with pandemic-era relief laws and continuing through more recent appropriations acts — repeatedly delayed the cycle that would have followed the 2022 reporting round. Congress ultimately updated the applicable data collection period to January through June 2025 ahead of this cycle, rather than requiring laboratories to report the older 2019 data a second time, producing the May 1 through July 31, 2026 reporting window in effect now.

Does this reporting requirement apply to laboratory tests performed for hospital inpatients? The applicable laboratory definition and reporting requirement are tied to how a laboratory bills Medicare, not to the care setting of any single patient. A hospital-based laboratory that bills the tests in question to Medicare Part B under its own NPI, and that independently meets the majority-of-Medicare-revenues and low-expenditure thresholds, can qualify as an applicable laboratory and carry reporting obligations regardless of whether the underlying patients were inpatients, outpatients, or outreach clients of that hospital's laboratory.

Organizations managing multi-state or multi-facility laboratory operations should also consider designating a single internal owner for PAMA reporting compliance going forward, given how frequently the specific deadlines and data collection periods have shifted across past cycles. A designated compliance lead who tracks CMS's CLFS & PAMA Reporting and Resources webpage on an ongoing basis, rather than reacting to periodic newsletter reminders like the one prompting this article, is better positioned to catch the next cycle's requirements early, register IDM accounts for the submitter and certifier roles well in advance, and avoid the compressed, deadline-driven scramble that has characterized parts of this reporting cycle's approach for laboratories that were not already tracking the requirement closely.